Analyst Information

 

David Amsellem

Sr. Research Analyst

David Amsellem

David Amsellem is a managing director and senior research analyst at Piper Jaffray covering specialty pharmaceuticals. Prior to joining Piper Jaffray in 2008, Amsellem spent five years at Friedman Billings Ramsey, where he was a senior research analyst covering small- and mid-cap pharmaceuticals from 2006-08 and a senior associate on the biotechnology equity research team from 2003-06. Amsellem has more than 15 years of Wall Street experience focused on the biopharmaceuticals space, with experience in life sciences investment and merchant banking prior to moving to the sell-side. Amsellem earned a bachelor's degree from Cornell University.

Associates:

Michael Ingerman
Research Analyst
Universe Coverage:
Healthcare:   Specialty Pharmaceuticals
ADMSAdamas Pharmaceuticals, Inc.
AKRXAkorn, Inc.
AGNAllergan plc
AMRXAmneal Pharmaceuticals Inc.
AMPHAmphastar Pharmaceuticals, Inc.
ATRSAntares Pharma, Inc.
BHCBausch Health Companies
CARACara Therapeutics Inc.
COLLCollegium Pharmaceutical, Inc.
DEPODepomed, Inc.
EGRXEagle Pharmaceuticals Inc.
ENDPEndo International plc
HZNPHorizon Pharma plc
INSYInsys Therapeutics, Inc.
JAZZJazz Pharmaceuticals plc
MNKMallinckrodt
MNLOMenlo Therapeutics Inc.
NBIXNeurocrine Biosciences Inc.
NOVNNovan, Inc.
OPTNOptiNose, Inc.
PCRXPacira Pharmaceuticals, Inc.
REPHRecro Pharma, Inc.
RVNCRevance Therapeutics, Inc.
SHPGShire plc
SUPNSupernus Pharmaceuticals, Inc.
TEVATeva Pharmaceutical Industries Limited